Update on KRdB Clinical Trial at Levine Cancer Institute | Shebli Atrash, MD | IMS 2023

Malignancies after Tandem ASCT for those on Total Therapy Protocols | Samer Al’Hadidi, MD | IMS 2023

Trends in 11;14 FISH Testing for Myeloma | Linda Baughn, PH.D. | IMS 2023

Managing Acute Immune Complications | Krina Patel, MD | IMS 2023

Update on Risk Stratification in MGUS and SMM | Doctors Callander and Beksac | IMS 2023

Study on Risk Stratification in Smoldering Myeloma Patients | Malin Hultcrantz, MD, PhD | IMS 2023

Wearable Tech for Early Detection of CRS in CAR T-cell Therapy | Sridevi Rajeeve, MD | IMS 2023

Real World Experiences of Patients Treated with Teclistamab | Shonali Midha, MD | IMS 2023

Using IMIDS and PIs to Treat at First Relapse | Paul Richardson, MD | IMS 2023

Immune Based Strategies to Improve Outcomes of Cellular Therapies | Rakesh Popat, PhD | IMS 2023

IMS Highlights for Triple Class Refractory Myeloma | Sagar Lonial, MD, FACP | IMS 2023

Optimizing Imaging in Multiple Myeloma | Jens Hillengass, MD | IMS 2023

A Comparative Study of Disparities in Myeloma Treatment Access | Matthew Leblanc, PHD, RN | IMS 2023

Managing CART-Cell Therapy in the Real World | Yi Lin, MD, PhD | IMS 2023

Results from the GMMG Concept Trial in Germany | Lisa Leypoldt, MD | IMS 2023

Changes in Weight in Induction Therapy | Ross Firestone, MD, PhD | IMS 2023